Novo Nordisk trims 11% of workforce to refocus on diabetes and obesity core
Danish multinational pharmaceutical company Novo Nordisk’s September restructuring marks its largest organisational reset in decades. The Denmark-based group is in the process of eliminating around 9,000 of 78,400 positions (c. 5,000 in Denmark) as it seeks to simplify decision-making, free up capital and defend leadership in the increasingly crowded GLP-1 diabetes-and-obesity arena. With headcount having risen 73 % since 2020, new…